sanofi rolls the bones

sanofi-aventis Group has seized an early stage opportunity that opened up when Biogen Idec Inc. recently refocused on neurology, by picking up an obesity and type 2 diabetes program centered on osteocalcin that was previously held by a Biogen incubator company. sanofi is funding external research to identify a receptor responsible for the hormone's metabolic effects and is internally devising strategies to develop osteocalcin or osteocalcin agonists as therapeutics.

In 2007, a team